EyeVision Pharma (EP) is using artificial intelligence drug combination platform to develop ocular restricted eyedrops to inhibit the axial elongation of the eye, underlying cause of myopia. Myopic vision can be corrected with devices, but cannot prevent the vision loss. Pharmaceutically, low-dose atropine is used for the treatment of myopia. However, recent disappointing results with atropine suggest there is an urgent need for a safe and effective pharmacological agent. Unlike managing symptoms or develop atropine formulations, EP is using: (i). AI-driven drug combination platform; (ii). Proprietary chemical linker and (iii). Proprietary pro-moiety library to develop eyedrops to prevent axial elongation.